CDKN2C
Overview
CDKN2C (Cyclin Dependent Kinase Inhibitor 2C, also known as p18-INK4C) encodes a CDK4/6 inhibitor that regulates the G1/S cell cycle transition by inhibiting cyclin D-CDK4/6 complexes, preventing RB phosphorylation and E2F activation. Located at 1p32.3, it is a known tumor suppressor in multiple myeloma (MM) where homozygous deletions are recurrent.
Alterations observed in the corpus
- Recurrent homozygous deletion at 1p32.3 in multiple myeloma (MM, n=153 patients with copy-number data); identified as one of the significant GISTIC peaks encompassing 32 genes across 7 regions; established MM tumor suppressor PMID:24434212
- Single-case CDKN2C mutation observed in PDTC/ATC thyroid cancer targeted sequencing cohort (IMPACT panel, 117 tumors), replicating prior WES ATC findings PMID:26878173
Cancer types (linked)
- Plasma cell myeloma (PCM/MM): recurrent homozygous deletion at 1p32.3; known MM tumor suppressor; loss of CDKN2C promotes CDK4/6-driven cell cycle entry in plasma cell tumors PMID:24434212
Co-occurrence and mutual exclusivity
- Homozygous deletion co-occurs in the broader context of cell-cycle dysregulation in MM; co-listed with TRAF3, BIRC2/BIRC3, CYLD, and PTPRD in significant GISTIC deletion peaks PMID:24434212
Therapeutic relevance
- CDKN2C loss would be expected to increase dependence on CDK4/6 activity; CDK4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) are potential therapeutic strategies in CDKN2C-deleted MM, though not yet established as standard of care PMID:24434212
Open questions
- Frequency of CDKN2C homozygous deletion and its interaction with other MM drivers (hyperdiploidy, IGH translocations) is not fully characterized in this cohort PMID:24434212
Sources
This page was processed by crosslinker on 2026-05-09. - PMID:26878173
This page was processed by entity-page-writer on 2026-05-15.